Discovery Laboratories, which is developing Aerosurf aerosolized KL4 surfactant for the treatment of respiratory distress syndrome (RDS) in premature infants, has announced several management changes.
Steven G. Simonson, who joined the company in May 2014, has been named Senior VP and Chief Development Officer and will oversee research, clinical and device development, regulatory affairs, and pharmacovigilance. The company also named Jan Mazela as Special Medical and Scientific Advisor, Neonatology and said that current Senior VP of R&D Russell G. Clayton will leave the company in December but will continue to advise the company on the Aerosurf development program through Phase 2.
Discovery Labs President and CEO John Cooper commented, “I believe that we have an outstanding medical team with the depth of expertise and experience required to advance Surfaxin and our Aerosurf development program, and to further the development of our pipeline of KL4 surfactant-based products for respiratory critical care. Dr. Simonson’s medical expertise in pulmonary critical care and clinical experience in developing respiratory drugs are essential skills for Discovery Labs. Further, we are excited to leverage Dr. Mazela’s passion for technical innovation in addressing the needs of neonates, including his significant experience with Surfaxin and expertise in the field of aerosolized surfactant delivery for newborns.”
Read the Discovery Labs press release.
